The new system technology allows active ingredients to work for a longer period of time than other, and is expected to improve the effectiveness of topical application in almost any field.
Greyson International CEO Harvey Tauman said the patent will support the company in moving forward with marketing and licensing agreements wherever active ingredients are needed.
"This trans-dermal delivery system could be used more effectively in cosmetic, medical and veterinary use," Tauman said.
Greyson originally submitted its application to the patent office in September 2009, and this approval puts Greyson’s Trilexon patent in force until September 2029.
